Defeat Duchenne Canada Launches New Clinical Trial Finder Tool
Defeat Duchenne Canada is proud to announce the launch of the first Clinical Trial Finder Tool for Duchenne and Becker muscular dystrophy in Canada.
Duchenne and Becker muscular dystrophy are progressive neuromuscular disorders with no cure. Affecting approximately 1 in every 5,000 boys in Canada, both Becker and Duchenne are caused by mutations within the dystrophin gene, one of the largest genes in the body responsible for strengthening muscles and protecting them from injury.
When the organization first began its quest for a cure twenty-six years ago, there was very little research and no clinical trials. Since then, numerous organizations, like Defeat Duchenne Canada, have transformed the landscape by investing in the most promising science focused on prevention, improved treatments, and a better quality of life for individuals living with Duchenne and Becker.
“We have developed an innovative Clinical Trial Finder Tool for those living with Duchenne and Becker muscular dystrophy. The tool helps gather comprehensive information on existing and pending clinical trials in Canada and beyond, allowing our community to easily personalize and navigate the latest information to help make informed choices about their participation,” shares Nicola Worsfold, Vice-President of Research, Advocacy and Education at Defeat Duchenne Canada.
“Being involved in a clinical trial is not a decision that can be made lightly,” she continues. “While it offers the possibility of hope, it also involves many sacrifices from the whole family. We want to empower our community with accurate, up-to-date information to facilitate informed decision making with their health care team.”
Watch the Defeat Duchenne Canada webinar launch of their Clinical Trial Finder Tool
Defeat Duchenne Canada has built a foundation of strong partnerships with leading scientists and industry partners to improve care for individuals living with Duchenne and Becker. When they heard the need from their community for more resources regarding clinical trials, the organization turned to Lumiio, a global digital health company specializing in real-world data collection services that drive health outcomes.
“We were thrilled to be able to work with Defeat Duchenne Canada in the development of a tool that helps close knowledge gaps around clinical trial opportunities,” said Josh Lounsberry, Chief Strategy Officer at Lumiio, “The needs of the Duchenne community align perfectly with Lumiio’s mission of accelerating health outcomes through data.”
Learn more about the Clinical Trial Finder Tool defeatduchenne.ca/clinicaltrials
Read next...
NMD4C Receive Excellence in Service Delivery Award and Network Investigators Honored as part of Muscular Dystrophy Canada’s 2024 Dr David Green Awards
We are excited to share that the NMD4C has been awarded the Excellence in Service Delivery Award, one of the annual Dr David Green Awards presented by Muscular Dystrophy Canada.
NMD4C Launch Canadian Neuromuscular Clinical Trial Network
We are thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work.
Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network
This past March 23, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered clinicians to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted.
MDC Announce Recipients of 2024 Neuromuscular Clinical and Translational Research Grants
Muscular Dystrophy Canada (MDC) recently announced the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects.
SMA Outcome Measures Training for Physiotherapists and Occupational Therapists
To support the development and training on validated NMD outcome measures we are pleased to provide opportunities for physiotherapists and occupational therapists to attend training sessions for outcome measures.
Congratulations to the 2024 NMD4C Early Career Awards Recipients
We are excited to announce the recipients of the 2024 NMD4C Early Career Awards! This is the second year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.